Market Cap
€133.6m
Last Updated
2019/10/14 20:52 UTC
Data Sources
Company Financials +
Executive Summary
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for use in out-patient and hospital-based sedation, anesthesia, and critical care services worldwide.
Snowflake
Fundamentals
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Paion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.0%
PA8
-0.5%
DE Biotechs
2.4%
DE Market
1 Year Return
-5.0%
PA8
5.0%
DE Biotechs
2.3%
DE Market
Return vs Industry: PA8 underperformed the German Biotechs industry which returned 5% over the past year.
Return vs Market: PA8 underperformed the German Market which returned 2.3% over the past year.
Shareholder returns
| PA8 | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.0% | -0.5% | 2.4% |
| 30 Day | -8.7% | -5.5% | -0.2% |
| 90 Day | -17.7% | -1.8% | 0.6% |
| 1 Year | -5.0%-5.0% | 5.1%5.0% | 5.5%2.3% |
| 3 Year | -28.7%-29.2% | 68.7%67.0% | 18.9%8.6% |
| 5 Year | -4.2%-5.0% | 21.6%18.8% | 44.8%25.1% |
Price Volatility Vs. Market
How volatile is Paion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Do Institutions Own Shares In Paion AG (ETR:PA8)?3 months ago | Simply Wall St
Does Paion AG's (ETR:PA8) CEO Pay Reflect Performance?4 months ago | Simply Wall St
Paion AG (ETR:PA8) Is Expected To BreakevenValuation
Is Paion undervalued compared to its fair value and its price relative to the market?
6.23x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: PA8 (€2.09) is trading above our estimate of fair value (€0.65)
Significantly Undervalued: PA8 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PA8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PA8 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate PA8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PA8 is overvalued based on its PB Ratio (6.2x) compared to the DE Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Paion forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
107.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PA8 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PA8 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PA8 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PA8's revenue (71.9% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: PA8's revenue (71.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: PA8's Return on Equity is forecast to be very high in 3 years time (63%).
Next Steps
Past Performance
How has Paion performed over the past 5 years?
6.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: PA8 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.4% per year.
Accelerating Growth: Unable to compare PA8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PA8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: PA8 has a negative Return on Equity (-14.54%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: PA8 is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: PA8 is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Paion's financial position?
Financial Position Analysis
Short Term Liabilities: PA8's short term assets (€23.4M) exceeds its short term liabilities (€4.3M)
Long Term Liabilities: PA8's short term assets (23.4M) exceeds its long term liabilities (29.9K)
Debt to Equity History and Analysis
Debt Level: PA8 is debt free.
Reducing Debt: PA8 had no debt 5 years ago.
Balance Sheet
Inventory Level: PA8 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PA8's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PA8 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PA8 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Paion's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate PA8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PA8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if PA8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PA8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PA8's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of Paion's salary, the management and board of directors tenure and is there insider trading?
3.8yrs
Average management tenure
CEO
Wolfgang Söhngen 0
3.8yrs
Tenure
€597,301
Compensation
Dr. Wolfgang Söhngen founded Paion AG in 2004 and serves as its Chief Executive Officer since December 31, 2015. Dr. Söhngen serves as the Chairman of Management Board at Paion AG. Dr. Söhngen is responsib ...
CEO Compensation Analysis
Compensation vs. Market: Wolfgang's total compensation ($USD658.26K) is about average for companies of similar size in the German market ($USD218.87K).
Compensation vs Earnings: Wolfgang's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.8yrs
Average Tenure
Experienced Management: PA8's management team is considered experienced (3.8 years average tenure).
Board Age and Tenure
2.3yrs
Average Tenure
59.5yo
Average Age
Experienced Board: PA8's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Wolfgang Söhngen
Founder
- Tenure: 3.8yrs
- Compensation: €597.30k
Jürgen Beck
Chief Development Officer & Member of Management Board
- Tenure: 1.8yrs
- Compensation: €422.13k
Ralf Penner
Vice President of Investor Relations & Public Relations
- Tenure: 0yrs
Abdelghani Omari (42yo)
CFO & Member of Management Board
- Tenure: 5.1yrs
- Compensation: €387.13k
Board Members
Jörg Spiekerkötter (61yo)
Chairman of Supervisory Board
- Tenure: 9.4yrs
- Compensation: €50.00k
Karin Louise Dorrepaal (58yo)
Vice Chairman of Supervisory Board
- Tenure: 0yrs
- Compensation: €37.50k
Chris Tanner (68yo)
Member of Supervisory Board
- Tenure: 2.3yrs
- Compensation: €25.00k
Markus Dieken
Member of Supervisory Board
- Tenure: 0.4yrs
Irina Antonijevic (54yo)
Member of Supervisory Board
- Tenure: 2.3yrs
- Compensation: €25.00k
Company Information
Paion AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Paion AG
- Ticker: PA8
- Exchange: XTRA
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €133.561m
- Shares outstanding: 63.90m
- Website: https://www.paion.com
Number of Employees
Location
- Paion AG
- Martinstrasse 10-12
- Aachen
- North Rhine-Westphalia
- 52062
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PA8 | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Feb 2005 |
| PAIO.F | OTCPK (Pink Sheets LLC) | Yes | Bearer Shares | US | USD | Feb 2005 |
| PA8 | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Feb 2005 |
| 0NF3 | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Feb 2005 |
| PA8D | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Feb 2005 |
Biography
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for use in out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company’s lead prod ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/14 20:52 |
| End of Day Share Price | 2019/10/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.